The progress during its first half focused on technologies for the automated scalable expansion of cartilaginous microtissues. A novel bioreactor was tested specifically for microtissue production and its integration to the automated platform. Results indicated that cartilaginous microtissues cultured in it exhibited similar properties to those cultured in AggreWell albeit faster. This novel bioreactor will support the production of sufficient microtissues to use in the large animal experiments, as well as to characterize and select the bio-printing technology for macro-tissue assembly.
A novel laser based process increased the capacity and throughput of the printing process by targeting specific cartilaginous microtissues. In addition, successful microtissue bioprinting was provided which is the first proof that this technology can be used for 3D cell aggregates/microtissues/organoids. For extrusion bioprinting, novel bioinks/hydrogels were used while the fusion of the microtissue was explored in addition to their capacity to host endothelial cells.
Essential hardware components and the corresponding material for the automated system were defined. Currently, the automated platform is in construction and integration with the bioprinter are underway. A novel cartridge for the continuous provision of microtissues suspensions during bioprinting has been enabled. Robotic-based experiments for cartilaginous microtissue differentiation were done with a liquid handler.
Future experiments and activities will focus on the integration of the single processes in a streamlined integrated process. The automated platform will be finalized and installed in order to produce and test microtissue-based osteochondral implants for assessment in the large animal models. Feasibility of the platform to produce the necessary amount and quality of microtissues will be the first priority. Subsequently, the functionality of the osteochondral implant will be evaluated in large animal models. The quality control panel, as developed in the first half will enable the characterization of the identity and regenerative capacity of the product. We expect that the microtissue-based product will result in healing and regeneration of deep osteochondral defects of the knee joint which is currently a challenge in the field.
Here are some key socio-economic impact and wider societal implications of Jointpromise to consider:
Improved Quality of Life: By providing effective cartilage implants, this project can improve quality of life for individuals suffering from OA. Patients will experience reduced pain, improved joint function, and increased mobility, allowing them to engage in daily activities and enjoy a more active lifestyle.
Economic Benefits: By offering large-scale cartilage implants, the project can reduce the need for expensive and recurrent treatments such as pain medications, physical therapy, and joint replacement surgeries.
Accessibility and Equity: This project can contribute to improving accessibility and equity in healthcare. OA affects individuals from all socio-economic backgrounds. By focusing on large-scale production, the project can aim for affordability and availability, ensuring that more patients can benefit from this innovative treatment.
